

Joaquin A Vizcarra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7327265/publications.pdf>

Version: 2024-02-01

30
papers

1,129
citations

471061

17
h-index

476904

29
g-index

30
all docs

30
docs citations

30
times ranked

1773
citing authors

#	ARTICLE	IF	CITATIONS
1	Movement disorders associated with neuronal antibodies: a data-driven approach. <i>Journal of Neurology</i> , 2022, 269, 3511-3521.	1.8	10
2	Childhood-Onset Hereditary Spastic Paraplegia (HSP): A Case Series and Review of Literature. <i>Pediatric Neurology</i> , 2022, 130, 7-13.	1.0	7
3	Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 4, 100091.	0.5	2
4	Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire. <i>Movement Disorders</i> , 2021, 36, 1392-1400.	2.2	16
5	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021, 97, e814-e824.	1.5	14
6	Update on Nodopathies of the Peripheral Nerve. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	1
7	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2021, 32, 159-167.	1.4	8
8	Quality of life in upper airway resistance syndrome. <i>Journal of Clinical Sleep Medicine</i> , 2021, , .	1.4	0
9	Internal Versus External Frame of Reference in Functional Movement Disorders. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 67-72.	0.9	5
10	Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 553635.	1.7	22
11	Development and Validation of the Orthostatic Tremor Severity and Disability Scale (<sc>OT</sc> >â€10). <i>Movement Disorders</i> , 2020, 35, 1796-1801.	2.2	7
12	Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2020, 94, 144-145.	1.5	2
13	Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 314-320.	0.9	50
14	COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. <i>Wellcome Open Research</i> , 2020, 5, 107.	0.9	31
15	COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. <i>Wellcome Open Research</i> , 2020, 5, 107.	0.9	19
16	Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects. <i>Journal of Neurology</i> , 2019, 266, 289-297.	1.8	39
17	Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease. <i>JAMA Network Open</i> , 2019, 2, e187800.	2.8	54
18	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α -synucleinopathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1257-1263.	0.9	73

#	ARTICLE	IF	CITATIONS
19	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , 2019, 34, 657-663.	2.2	213
20	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	2.2	43
21	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.5	194
22	OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 174-178.	1.1	13
23	Small intestinal bacterial overgrowth in Parkinson's disease: Tribulations of a trial. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 110-112.	1.1	29
24	Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S53-S56.	1.1	63
25	Orthostatic hypotension in Parkinson disease: Impact on health care utilization. <i>Parkinsonism and Related Disorders</i> , 2018, 47, 45-49.	1.1	30
26	Technology-based assessment of motor and nonmotor phenomena in Parkinson disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 825-845.	1.4	31
27	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	2.2	36
28	Vascular Parkinsonism: Deconstructing a Syndrome. <i>Movement Disorders</i> , 2015, 30, 886-894.	2.2	88
29	The power in numbers: Gut microbiota in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 296-298.	2.2	25
30	Treatment Issues in Multiple Sclerosis in Latin America. <i>Neuroepidemiology</i> , 2015, 44, 66-68.	1.1	4